**Supplementary Materials**

**Table S1**

**Prior Therapies**

|  |  |  |
| --- | --- | --- |
|  | **Prior Nephrectomy** | **No Prior Nephrectomy** |
| **Cabozantinib****(N=283)** | **Everolimus****(N=279)** | **Cabozantinib****(N=47)** | **Everolimus****(N=49)** |
| Number of VEGFR TKIs, n (%) |
| 1 | 201 (71)  | 190 (68) | 34 (72) | 39 (80) |
| 2 or more | 82 (29)  | 89 (32) | 13 (28) | 10 (20) |
| VEGFR TKI, % |
| Sunitinib | 183 (65)  | 179 (64) | 27 (57) | 26 (53) |
| Pazopanib | 122 (43)  | 113 (41) | 22 (47) | 23 (47) |
| Axitinib | 45 (16)  | 49 (18) | 7 (15) | 6 (12) |
| Sorafenib | 17 (6)  | 29 (10) | 4 (9) | 2 (4) |
| Other therapy, % |
| Radiotherapy | 93 (33)  | 90 (32) | 17 (36) | 18 (37) |
| Interleukins | 18 (6)  | 28 (10) | 2 (4) | 1 (2) |
| Interferons | 16 (6) | 24 (9) | 3 (6) | 0 |
| Nivolumab | 16 (6) | 11 (4) | 2 (4) | 3 (6) |
| Bevacizumab | 5 (2) | 10 (4) | 0 | 1 (2) |

TKI, tyrosine kinase inhibitor; VEGFR, vascular endothelial growth factor receptor.

**Table S2**

**Subsequent Cancer Therapy**

|  |  |  |
| --- | --- | --- |
|  | **Prior Nephrectomy** | **No Prior Nephrectomy** |
| **Cabozantinib****(N=283)** | **Everolimus****(N=279)** | **Cabozantinib****(N=47)** | **Everolimus****(N=49)** |
| Any systemic anti-cancer therapy, n (%) | 143 (51)  | 152 (54) | 22 (47) | 29 (59) |
| Any VEGFR TKI | 63 (22)  | 130 (47) | 14 (30) | 26 (53) |
| Axitinib | 45 (16)  | 73 (26) | 10 (21) | 17 (35) |
| Sunitinib | 15 (5)  | 30 (11) | 2 (4) | 3 (6) |
| Sorafenib | 8 (3) | 26 (9) | 1 (2) | 5 (10) |
| Pazopanib | 4 (1) | 19 (7) | 1 (2) | 3 (6) |
| Cabozantinib | 0 | 7 (3) | 0 | 1 (2) |
| Everolimus | 86 (30)  | 14 (5) | 9 (19) | 0 |
| Bevacizumab | 8 (3) | 8 (3) | 0 | 3 (6) |
| PD-1/PD-L1 targeting agents | 11 (4) | 13 (5) | 4 (9) | 5 (10) |

PD-1, programmed cell death-1; PD-L1, programmed death-ligand 1; TKI, tyrosine kinase inhibitor; VEGFR, vascular endothelial growth factor receptor.